Cancer Drug Resistance

Cancer Drug Resistance

癌症药物耐药性

  • 3区 中科院分区
  • Q1 JCR分区

期刊简介

《Cancer Drug Resistance》是由OAE Publishing Inc.出版社于2018年创办的英文国际期刊(ISSN: 2578-532X),该期刊长期致力于肿瘤学领域的创新研究,主要研究方向为ONCOLOGY。作为SCIE收录期刊(JCR分区 Q1,中科院 3区),本刊采用OA未开放获取模式以发表肿瘤学领域等方向的原创性研究为核心(研究类文章占比44.44%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在63篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Cancer Drug Resistance该刊近年未被列入国际预警名单,年发文量约63篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 63 发文量

中科院分区

《新锐期刊分区表》(2026年3月发布)

Top期刊 综述期刊 大类学科 小类学科
医学
3区
ONCOLOGY 肿瘤学 PHARMACOLOGY & PHARMACY 药学
3区 3区

期刊分区表(2025年3月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
4区
ONCOLOGY 肿瘤学
4区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY ESCI Q1 50 / 333

85.1

学科:ONCOLOGY ESCI Q2 99 / 333

70.42

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY ESCI Q1 76 / 322

76.6

学科:ONCOLOGY ESCI Q3 174 / 322

46.12

CiteScore(2026年6月最新版)

CiteScore SJR SNIP CiteScore 排名
CiteScore:10.3 SJR:1.775 SNIP:1.124
学科类别 分区 排名 百分位
大类:Medicine 小类:Pharmacology (medical) Q1 20 / 278

92%

大类:Medicine 小类:Cancer Research Q1 46 / 233

80%

期刊发文

  • Advances in the application of patient-derived models in acute leukemia resistanc

    Author: Qin, Ronghao; Liang, Yuxing; Zhou, Fuling

    Journal: CANCER DRUG RESISTANCE. 2025; Vol. 8, Issue , pp. -. DOI: 10.20517/cdr.2025.18

  • Antibody-drug conjugates in breast cancer: current resistance mechanisms and future combination strategie

    Author: Xing, Ping; Yang, Chenghui; Hu, Hanwen; Qian, Tianyi; Xie, Bojian; Huang, Jian; Wang, Zhen

    Journal: CANCER DRUG RESISTANCE. 2025; Vol. 8, Issue , pp. -. DOI: 10.20517/cdr.2025.26

  • MicroRNA-mediated autophagy regulation in thyroid cancer drug resistanc

    Author: Huang, Dongye; Liu, Qianwen; Liu, Chang; Cao, Jingna; Zhang, Senmin; Cao, Huijiao; Chen, Wenkuan

    Journal: CANCER DRUG RESISTANCE. 2025; Vol. 8, Issue , pp. -. DOI: 10.20517/cdr.2025.73

  • Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformatio

    Author: Yu, Jinglu; Kong, Xiaoni; Feng, Yu

    Journal: CANCER DRUG RESISTANCE. 2025; Vol. 8, Issue , pp. -. DOI: 10.20517/cdr.2025.14

  • Ivosidenib enhances cisplatin sensitivity in ovarian cancer by reducing cancer cell stemnes

    Author: Chen, Mengqing; Huang, Lin; Zhao, Simei; Zhu, Mengna; Sun, Si; Li, Wenhan; Cai, Jing; Peng, Minggang; Wen, Yiping; Wang, Zehua

    Journal: CANCER DRUG RESISTANCE. 2025; Vol. 8, Issue , pp. -. DOI: 10.20517/cdr.2025.51

  • Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cance

    Author: Su, Juncheng; Wang, Jiahui; Chen, Weilin; Xu, Yingjie; Yang, Wen; Liu, Weiwei; Wang, Zheng; Huang, Masha

    Journal: CANCER DRUG RESISTANCE. 2025; Vol. 8, Issue , pp. -. DOI: 10.20517/cdr.2025.35

  • Exploring YAP1-related TIME in SCLC: implications for survival and treatment response to immunochemotherap

    Author: Chen, Yu-Qing; Tan, Jia-Xiong; Gao, Ling-Ling; Yang, Jia-Xing; Huang, Jie; Yang, Jin-Ji; Zhao, Qiang

    Journal: CANCER DRUG RESISTANCE. 2025; Vol. 8, Issue , pp. -. DOI: 10.20517/cdr.2024.177

  • Sophisticated roles of tumor microenvironment in resistance to immune checkpoint blockade therapy in hepatocellular carcinom

    Author: Zhang, Yi-Zhe; Ma, Yunshu; Ma, Ensi; Chen, Xizhi; Zhang, Yue; Yin, Baobing; Zhao, Jing

    Journal: CANCER DRUG RESISTANCE. 2025; Vol. 8, Issue , pp. -. DOI: 10.20517/cdr.2024.165